Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

20072,928 citationsJournal Articlebronze Open Access

Authors

Dennis M. Black · University of California, San Francisco

Pierre D. Delmas · Université Claude Bernard Lyon 1

Richard Eastell · University of Sheffield

Ian R. Reid · University of Auckland

Steven Boonen · KU Leuven

Jane A. Cauley · University of Pittsburgh

Felicia Cosman ·

Abstract

A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)

Topics & Keywords

Bone health and osteoporosis research Bone health and treatments Bone Metabolism and Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 356, Issue 18, pp. 1809-1822

DOI: 10.1056/nejmoa067312

Field-Weighted Citation Impact: 183.95